Patents by Inventor Steven A. Rosenberg

Steven A. Rosenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Writing electronic paper
    Patent number: 10538111
    Abstract: Embodiments of the present invention are directed to systems and methods for writing on electronic paper (“e-paper”) and display platforms implemented with e-paper. In one aspect, a system for writing information to electronic paper includes a writing module and an erasing unit connected to the writing module. The erasing unit is configured to erase information stored in the electronic paper. The system also includes a writing unit connected to the writing module and is configured to write information to the electronic paper. Information is written to the electronic paper by orienting the writing module so that the electronic paper passes the erasing unit prior to passing the writing unit.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: January 21, 2020
    Assignee: Hewlett-Packard Development Company, L.P.
    Inventors: Omer Gila, Napoleon J. Leoni, Steven Rosenberg, Henryk Birecki
  • METHODS OF PREPARING AN ISOLATED POPULATION OF DENDRITIC CELLS AND METHODS OF TREATING CANCER USING SAME
    Publication number: 20200017831
    Abstract: Disclosed are methods of preparing an isolated population of dendritic cells, isolated populations of dendritic cells prepared by the methods, and pharmaceutical compositions comprising the isolated population of dendritic cells. Also disclosed are methods of treating or preventing cancer using the isolated population of dendritic cells or pharmaceutical compositions.
    Type: Application
    Filed: September 18, 2017
    Publication date: January 16, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Gal Cafri, Paul F. Robbins, Jared J. Gartner, Steven A. Rosenberg
  • VIRAL METHODS OF T CELL THERAPY
    Publication number: 20190374576
    Abstract: Methods of producing a population of genetically modified cells using viral or non-viral vectors. Disclosed are also modified viruses for producing a population of genetically modified cells and/or for the treatment of cancer.
    Type: Application
    Filed: April 19, 2019
    Publication date: December 12, 2019
    Inventors: Thomas HENLEY, Eric RHODES, Modassir CHOUDHRY, Branden MORIARITY, Beau WEBBER, Steven A. ROSENBERG, Douglas C. PALMER, Nicholas P. RESTIFO
  • METHODS OF GROWING TUMOR INFILTRATING LYMPHOCYTES IN GAS-PERMEABLE CONTAINERS
    Publication number: 20190345444
    Abstract: An embodiment of the invention provides a method of promoting regression of cancer in a mammal comprising obtaining a tumor tissue sample from the mammal; culturing the tumor tissue sample in a first gas permeable container containing cell medium therein; obtaining tumor infiltrating lymphocytes (TIL) from the tumor tissue sample; expanding the number of TIL in a second gas permeable container containing cell medium therein using irradiated allogeneic feeder cells and/or irradiated autologous feeder cells; and administering the expanded number of TIL to the mammal. Methods of obtaining an expanded number of TIL from a mammal for adoptive cell immunotherapy are also provided.
    Type: Application
    Filed: December 6, 2018
    Publication date: November 14, 2019
    Inventors: Steven A. Rosenberg, Mark E. Dudley, David Stroncek, Marianna Sabatino, Jianjian Jin, Robert Somerville, John R. Wilson
  • Methods and Compositions for Determining Smoking Status
    Publication number: 20190311808
    Abstract: Peripheral blood markers are provided whose expression levels correlate with smoking status. Predictive models developed using highly informative markers are disclosed, along with systems, kits, and methods for using the markers to provide a biochemical surrogate for a subject's smoking status.
    Type: Application
    Filed: April 11, 2019
    Publication date: October 10, 2019
    Inventors: Steven Rosenberg, Michael Reid Elashoff, Phillip Beineke, James A. JWingrove
  • ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS
    Publication number: 20190309043
    Abstract: Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: May 10, 2019
    Publication date: October 10, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • VINYL AROMATIC RESIN
    Publication number: 20190292285
    Abstract: Provided is vinyl aromatic resin comprising benzyl alcohol groups, benzyl ether groups, and methylene bridge groups, wherein the mole ratio of the benzyl ether groups to the methylene bridge groups is from 0.002:1 to 0.1:1, wherein the vinyl aromatic resin either has no amine groups or else has amine groups in a mole ratio of the sum of all amine groups to aromatic rings of 0.1:1 or lower.
    Type: Application
    Filed: June 19, 2017
    Publication date: September 26, 2019
    Inventors: G. Leslie Burnett, Javier Read De Alaniz, John C. Rohanna, Alfred K. Schultz, Steven Rosenberg
  • Modified cells and methods of therapy
    Patent number: 10406177
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: September 10, 2019
    Assignees: Regents of the University of Minnesota, Intima Bioscience, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Branden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
  • Murine anti-NY-ESO-1 T cell receptors
    Patent number: 10407485
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a mammal and a method of treating or preventing cancer in a mammal using the inventive TCRs or related materials.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: September 10, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Maria R. Parkhurst, Richard A. Morgan, Steven A. Rosenberg, Shannon Faith Rosati
  • Filtration assembly including spiral wound bioreactors and membrane modules positioned in separate pressure vessels
    Patent number: 10335737
    Abstract: A filtration assembly including: a hyperfiltration assembly including: a high pressure vessel including a feed port, concentrate port and permeate port, and a plurality of serially arranged spiral wound hyperfiltration membrane modules; a bioreactor assembly including: a low pressure vessel comprising a first and second port, and a plurality of spiral wound bioreactors located within the low pressure vessel with each bioreactor comprising a flat sheet having two opposing bio-growth surfaces and a feed spacer spirally wound about an axis; and a fluid flow pathway extending from a fluid feed source: into the first port of the low pressure vessel, through the bioreactors and out the second port of the low pressure vessel, and into the feed port of the high pressure vessel, through the membrane modules and out of the concentrate port and permeate port.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: July 2, 2019
    Assignee: DOW GLOBAL TECHNOLOGIES LLC
    Inventors: Steven D. Jons, Jon E. Johnson, Steven Rosenberg
  • Anti-human papillomavirus 16 E6 T cell receptors
    Patent number: 10329339
    Abstract: Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: June 25, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Methods of conditioning patients for T cell therapy
    Patent number: 10322146
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: June 18, 2019
    Assignees: Kite Pharma, Inc., The United States of America as Represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
  • ANTI-KRAS-G12D T CELL RECEPTORS
    Publication number: 20190177395
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: July 31, 2017
    Publication date: June 13, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Service
    Inventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
  • METHODS OF PREPARING ANTI-HUMAN PAPILLOMAVIRUS ANTIGEN T CELLS
    Publication number: 20190117761
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 25, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
    Patent number: 10251912
    Abstract: The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: April 9, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Rong-Fu Wang, Steven A. Rosenberg, Gang Zeng
  • HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS
    Publication number: 20190085046
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: September 19, 2018
    Publication date: March 21, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Rami Yoseph, Gal Cafri, Paul F. Robbins, Steven A. Rosenberg
  • ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS
    Publication number: 20190085047
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: November 30, 2018
    Publication date: March 21, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Service
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY
    Publication number: 20190060363
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Application
    Filed: November 6, 2018
    Publication date: February 28, 2019
    Inventors: Branden MORIARITY, Beau WEBBER, Modassir CHOUDHRY, Steven A. ROSENBERG, Douglas C. PALMER, Nicholas P. RESTIFO
  • INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY
    Publication number: 20190060364
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Application
    Filed: November 6, 2018
    Publication date: February 28, 2019
    Inventors: Branden MORIARITY, Beau WEBBER, Modassir CHOUDHRY, Steven A. Rosenberg, Douglas C. PALMER, Nicholas P. RESTIFO
  • ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE
    Publication number: 20190054143
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
    Type: Application
    Filed: October 29, 2018
    Publication date: February 21, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Richard A. Morgan, Dhanalakshmi Dhanalakshmi, Steven A. Rosenberg